MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

Standard

MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT). / Hillengass, Jens; Cohen, Adam D; Delforge, Michel; Einsele, Hermann; Goldschmidt, Hartmut; Weisel, Katja; Raab, Marc-Steffen; Scheid, Christof; Schecter, Jordan M; de Braganca, Kevin C; Varsos, Helen; Yeh, Tzu-Min; Mistry, Pankaj; Roccia, Tito; Corsale, Christina; Akram, Muhammad; Pacaud, Lida; Nesheiwat, Tonia; Agha, Mounzer; Cohen, Yael C.

in: CL LYMPH MYELOM LEUK, Jahrgang 22, Nr. Suppl 2, S411, 01.10.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Hillengass, J, Cohen, AD, Delforge, M, Einsele, H, Goldschmidt, H, Weisel, K, Raab, M-S, Scheid, C, Schecter, JM, de Braganca, KC, Varsos, H, Yeh, T-M, Mistry, P, Roccia, T, Corsale, C, Akram, M, Pacaud, L, Nesheiwat, T, Agha, M & Cohen, YC 2022, 'MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)', CL LYMPH MYELOM LEUK, Jg. 22, Nr. Suppl 2, S411. https://doi.org/10.1016/S2152-2650(22)01600-7

APA

Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M-S., Scheid, C., Schecter, J. M., de Braganca, K. C., Varsos, H., Yeh, T-M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M., & Cohen, Y. C. (2022). MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT). CL LYMPH MYELOM LEUK, 22(Suppl 2), [S411]. https://doi.org/10.1016/S2152-2650(22)01600-7

Vancouver

Bibtex

@article{615100231cec42c188cc2fb82ed80e39,
title = "MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)",
abstract = "CONTEXT: CARTITUDE-2 (NCT04133636) Cohort A is assessing cilta-cel in lenalidomide-refractory patients with progressive MM after 1-3 prior LOT.OBJECTIVE: To present updated results from CARTITUDE-2 Cohort A.DESIGN: Phase 2, multicohort study.PATIENTS: Lenalidomide-refractory patients with progressive MM after 1-3 prior LOT (PI and IMiD included) and no previous exposure to BCMA-targeting agents.INTERVENTIONS: Single cilta-cel infusion (target dose 0.75×106 CAR+ viable T-cells/kg) after lymphodepletion Main Outcome Measures: Primary endpoint was minimal residual disease (MRD) negativity at 10-5. Management strategies were used to reduce risk of movement/neurocognitive adverse events (MNTs). Pharmacokinetics (PK) (Cmax/Tmax of CAR+T-cell transgene levels), cytokine release syndrome (CRS)-related cytokines over time, peak cytokine levels by response/CRS, association of cytokine levels with immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR+T-cell CD4/CD8 ratio by response/CRS/ICANS are being evaluated.RESULTS: As of January 2022 (median follow-up [MFU] 17.1 months), 20 patients (65% male; median age 60 years; median 2 prior LOT; 95% refractory to last LOT) received cilta-cel. Overall response rate was 95% (90% ≥complete response; 95% ≥very good partial response). Median times to first and best response were 1.0 month and 2.6 months, respectively. All 16 MRD-evaluable patients achieved MRD negativity at 10-5. Median duration of response was not reached. At 12 months, event-free rate was 79% and progression-free survival rate was 75%. 95% of patients had CRS (gr3/4 10%); median time to onset was 7 days and median duration was 3 days. Neurotoxicity was reported in 30% of patients (5 gr1/2; 1 gr3/4) and ICANS in 15% (all 3 gr1/2); 1 patient had gr2 facial paralysis. No MNTs were observed. 1 death occurred due to COVID-19 (treatment-related), 2 due to progressive disease, and 1 due to sepsis (not treatment-related). Preliminary PK analyses showed peak CAR-T cell expansion at day 10.5; median persistence was 153.5 days.CONCLUSIONS: At MFU of 17.1 months, a single cilta-cel infusion resulted in deep and durable responses in lenalidomide-refractory MM patients with 1-3 prior LOT. We will present updated PK/cytokine/CAR-T subset analyses and clinical correlation to provide novel insights into biological correlates of efficacy/safety in this population.",
keywords = "B-Cell Maturation Antigen/therapeutic use, COVID-19, Cytokines, Female, Humans, Immunotherapy, Adoptive/adverse effects, Lenalidomide/pharmacology, Male, Middle Aged, Multiple Myeloma/drug therapy, Receptors, Chimeric Antigen",
author = "Jens Hillengass and Cohen, {Adam D} and Michel Delforge and Hermann Einsele and Hartmut Goldschmidt and Katja Weisel and Marc-Steffen Raab and Christof Scheid and Schecter, {Jordan M} and {de Braganca}, {Kevin C} and Helen Varsos and Tzu-Min Yeh and Pankaj Mistry and Tito Roccia and Christina Corsale and Muhammad Akram and Lida Pacaud and Tonia Nesheiwat and Mounzer Agha and Cohen, {Yael C}",
note = "Copyright {\textcopyright} 2022 Elsevier Inc. All rights reserved.",
year = "2022",
month = oct,
day = "1",
doi = "10.1016/S2152-2650(22)01600-7",
language = "English",
volume = "22",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "Suppl 2",

}

RIS

TY - JOUR

T1 - MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

AU - Hillengass, Jens

AU - Cohen, Adam D

AU - Delforge, Michel

AU - Einsele, Hermann

AU - Goldschmidt, Hartmut

AU - Weisel, Katja

AU - Raab, Marc-Steffen

AU - Scheid, Christof

AU - Schecter, Jordan M

AU - de Braganca, Kevin C

AU - Varsos, Helen

AU - Yeh, Tzu-Min

AU - Mistry, Pankaj

AU - Roccia, Tito

AU - Corsale, Christina

AU - Akram, Muhammad

AU - Pacaud, Lida

AU - Nesheiwat, Tonia

AU - Agha, Mounzer

AU - Cohen, Yael C

N1 - Copyright © 2022 Elsevier Inc. All rights reserved.

PY - 2022/10/1

Y1 - 2022/10/1

N2 - CONTEXT: CARTITUDE-2 (NCT04133636) Cohort A is assessing cilta-cel in lenalidomide-refractory patients with progressive MM after 1-3 prior LOT.OBJECTIVE: To present updated results from CARTITUDE-2 Cohort A.DESIGN: Phase 2, multicohort study.PATIENTS: Lenalidomide-refractory patients with progressive MM after 1-3 prior LOT (PI and IMiD included) and no previous exposure to BCMA-targeting agents.INTERVENTIONS: Single cilta-cel infusion (target dose 0.75×106 CAR+ viable T-cells/kg) after lymphodepletion Main Outcome Measures: Primary endpoint was minimal residual disease (MRD) negativity at 10-5. Management strategies were used to reduce risk of movement/neurocognitive adverse events (MNTs). Pharmacokinetics (PK) (Cmax/Tmax of CAR+T-cell transgene levels), cytokine release syndrome (CRS)-related cytokines over time, peak cytokine levels by response/CRS, association of cytokine levels with immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR+T-cell CD4/CD8 ratio by response/CRS/ICANS are being evaluated.RESULTS: As of January 2022 (median follow-up [MFU] 17.1 months), 20 patients (65% male; median age 60 years; median 2 prior LOT; 95% refractory to last LOT) received cilta-cel. Overall response rate was 95% (90% ≥complete response; 95% ≥very good partial response). Median times to first and best response were 1.0 month and 2.6 months, respectively. All 16 MRD-evaluable patients achieved MRD negativity at 10-5. Median duration of response was not reached. At 12 months, event-free rate was 79% and progression-free survival rate was 75%. 95% of patients had CRS (gr3/4 10%); median time to onset was 7 days and median duration was 3 days. Neurotoxicity was reported in 30% of patients (5 gr1/2; 1 gr3/4) and ICANS in 15% (all 3 gr1/2); 1 patient had gr2 facial paralysis. No MNTs were observed. 1 death occurred due to COVID-19 (treatment-related), 2 due to progressive disease, and 1 due to sepsis (not treatment-related). Preliminary PK analyses showed peak CAR-T cell expansion at day 10.5; median persistence was 153.5 days.CONCLUSIONS: At MFU of 17.1 months, a single cilta-cel infusion resulted in deep and durable responses in lenalidomide-refractory MM patients with 1-3 prior LOT. We will present updated PK/cytokine/CAR-T subset analyses and clinical correlation to provide novel insights into biological correlates of efficacy/safety in this population.

AB - CONTEXT: CARTITUDE-2 (NCT04133636) Cohort A is assessing cilta-cel in lenalidomide-refractory patients with progressive MM after 1-3 prior LOT.OBJECTIVE: To present updated results from CARTITUDE-2 Cohort A.DESIGN: Phase 2, multicohort study.PATIENTS: Lenalidomide-refractory patients with progressive MM after 1-3 prior LOT (PI and IMiD included) and no previous exposure to BCMA-targeting agents.INTERVENTIONS: Single cilta-cel infusion (target dose 0.75×106 CAR+ viable T-cells/kg) after lymphodepletion Main Outcome Measures: Primary endpoint was minimal residual disease (MRD) negativity at 10-5. Management strategies were used to reduce risk of movement/neurocognitive adverse events (MNTs). Pharmacokinetics (PK) (Cmax/Tmax of CAR+T-cell transgene levels), cytokine release syndrome (CRS)-related cytokines over time, peak cytokine levels by response/CRS, association of cytokine levels with immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR+T-cell CD4/CD8 ratio by response/CRS/ICANS are being evaluated.RESULTS: As of January 2022 (median follow-up [MFU] 17.1 months), 20 patients (65% male; median age 60 years; median 2 prior LOT; 95% refractory to last LOT) received cilta-cel. Overall response rate was 95% (90% ≥complete response; 95% ≥very good partial response). Median times to first and best response were 1.0 month and 2.6 months, respectively. All 16 MRD-evaluable patients achieved MRD negativity at 10-5. Median duration of response was not reached. At 12 months, event-free rate was 79% and progression-free survival rate was 75%. 95% of patients had CRS (gr3/4 10%); median time to onset was 7 days and median duration was 3 days. Neurotoxicity was reported in 30% of patients (5 gr1/2; 1 gr3/4) and ICANS in 15% (all 3 gr1/2); 1 patient had gr2 facial paralysis. No MNTs were observed. 1 death occurred due to COVID-19 (treatment-related), 2 due to progressive disease, and 1 due to sepsis (not treatment-related). Preliminary PK analyses showed peak CAR-T cell expansion at day 10.5; median persistence was 153.5 days.CONCLUSIONS: At MFU of 17.1 months, a single cilta-cel infusion resulted in deep and durable responses in lenalidomide-refractory MM patients with 1-3 prior LOT. We will present updated PK/cytokine/CAR-T subset analyses and clinical correlation to provide novel insights into biological correlates of efficacy/safety in this population.

KW - B-Cell Maturation Antigen/therapeutic use

KW - COVID-19

KW - Cytokines

KW - Female

KW - Humans

KW - Immunotherapy, Adoptive/adverse effects

KW - Lenalidomide/pharmacology

KW - Male

KW - Middle Aged

KW - Multiple Myeloma/drug therapy

KW - Receptors, Chimeric Antigen

U2 - 10.1016/S2152-2650(22)01600-7

DO - 10.1016/S2152-2650(22)01600-7

M3 - SCORING: Journal article

C2 - 36164151

VL - 22

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

IS - Suppl 2

M1 - S411

ER -